Neuromyelitis optica spectrum disorder surgery
|
Neuromyelitis optica spectrum disorder Microchapters |
|
Differentiating Neuromyelitis optica spectrum disorder from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neuromyelitis optica spectrum disorder surgery On the Web |
|
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder surgery |
|
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder |
|
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
Surgery has no established role in treating the underlying inflammation of neuromyelitis optica spectrum disorder (NMOSD). The mainstay of treatment is medical therapy for acute attacks and prevention of relapses.[1]
Selected procedures may be considered to manage disabling complications. For attack treatment and preventive immunotherapy, see medical therapy.
Surgery
Severe Spasticity
Neuromyelitis optica spectrum disorder may cause persistent spasticity after myelitis. Intrathecal baclofen (ITB), delivered through an implanted pump, is a possible treatment for selected patients with severe spasticity. Goals include improving comfort, reducing spasms, and facilitating care. Evidence specific to NMOSD is limited; patient selection draws on broader spasticity-management experience.[2]
Refractory Neurogenic Bladder Dysfunction
Neuromyelitis optica spectrum disorder complicated by refractory neurogenic bladder dysfunction may require specialist urological assessment. The 2026 European Association of Urology (EAU) neuro-urology guidelines provide general guidance for these complications; they are not NMOSD-specific surgical recommendations.[3]
- Bladder augmentation: An option for low bladder compliance or refractory neurogenic detrusor overactivity when less-invasive treatments have failed.[3]
- Urinary diversion: May be considered when other treatments are unsuccessful, particularly when protection of the upper urinary tract is necessary.[3]
Brain or Spinal Cord Biopsy
Neuromyelitis optica spectrum disorder does not ordinarily require brain or spinal cord biopsy. The International Panel for Neuromyelitis Optica Diagnosis (IPND) does not recommend routine central nervous system biopsy. In atypical cases, expert review of available biopsy tissue may help establish the diagnosis and exclude competing disorders.[4]
Indications
Neuromyelitis optica spectrum disorder may warrant assessment for a procedure when a specific complication is refractory to treatment or threatens organ function:
- Baclofen pump implantation: Severe spasticity of spinal origin that responds inadequately to oral baclofen, or for which effective oral doses cause intolerable adverse effects. A positive response to an intrathecal screening trial is required before permanent pump implantation.[5]
- Urological surgery: Refractory bladder dysfunction, low bladder compliance, or threatened upper urinary tract function after appropriate conservative, pharmacological, and less-invasive treatment.[3]
Contraindications and Precautions
Neuromyelitis optica spectrum disorder patients considered for a procedure require assessment of the specific intervention's risks and follow-up requirements.
- Infection: Patients should be infection-free before an ITB screening trial or baclofen pump implantation.[5]
- Pump maintenance: Reliable access to refills and device follow-up is essential. Abrupt interruption of ITB can cause life-threatening withdrawal.[5]
- Urological reconstruction: Assess the potential need for intermittent catheterization and the ability to maintain long-term follow-up. Bladder augmentation requires lifelong surveillance because of its potential complications.[3]
References
- ↑ Kümpfel T, Giglhuber K, Aktas O, et al. (2024). "Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management". Journal of Neurology. 271: 141–176. doi:10.1007/s00415-023-11910-z. PMC 10770020 Check
|pmc=value (help). - ↑ Abboud H, Salazar-Camelo A, George N, et al. (2022). "Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders". Journal of Neurology. 269 (4): 1786–1801. doi:10.1007/s00415-021-10783-4. PMC 8940781 Check
|pmc=value (help). PMID 34482456 Check|pmid=value (help). - ↑ 3.0 3.1 3.2 3.3 3.4 European Association of Urology (2026). "EAU Guidelines on Neuro-urology: The Guideline". Uroweb. Section 3.4.3: Surgical treatment. Retrieved 2026-10-30.
- ↑ Wingerchuk DM, Banwell B, Bennett JL, et al. (2015). "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders". Neurology. 85 (2): 177–189. doi:10.1212/WNL.0000000000001729. PMC 4515040. PMID 26092914.
- ↑ 5.0 5.1 5.2 "GABLOFEN (baclofen injection, for intrathecal use): prescribing information". DailyMed. U.S. National Library of Medicine. Retrieved 2026-10-30.